Produktname:6-Amino-3-bromo-2-methylbenzoic acid
IUPAC Name:6-amino-3-bromo-2-methylbenzoic acid
- CAS：124341-06-6
- Molekulare Formel：C8H8BrNO2
- Reinheit：95%
- Katalognummer：CM248452
- Molekulargewicht：230.06
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:124341-06-6
- Molekulare Formel:C8H8BrNO2
- Schmelzpunkt:-
- SMILES-Code:O=C(O)C1=C(N)C=CC(Br)=C1C
- Dichte:
- Katalognummer:CM248452
- Molekulargewicht:230.06
- Siedepunkt:346.4±42.0°C at 760 mmHg
- Mdl-Nr.:
- Lagerung:Store at 2-8°C.
Category Infos
- Benzenes
- Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Column Infos
- Tinlorafenib
- The Journal of Medicinal Chemistry releases an article titled "Identification of the Clinical Candidate PF-07284890 (ARRY-461), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer". Mutations in the BRAF gene result in MAPK pathway activation that are most commonly found in human melanomas. The BRAF V600E mutation is among the most frequent types. Present BRAF inhibitors have significantly improved treatment outcomes for patients with BRAF V600-mutant cancers. However, their effectiveness is limited by disease progression in the brain as they don’t adequately penetrate the blood-brain barrier (BBB).
Pfizer’s Tinlorafenib (formerly PF 07284890) is a highly brain-penetrant inhibitor of BRAF V600-mutant tumors, and currently in a phase 1 clinical trial (NCT04543188).
Suche 
+86 21 5895 0110 
